Fusion Antibodies (LON:FAB) Shares Up 2% – Still a Buy?

Shares of Fusion Antibodies plc (LON:FAB) traded up 2% during mid-day trading on Tuesday . The stock traded as high as GBX 11.40 and last traded at GBX 10.71. 159,643 shares traded hands during trading, a decline of 60% from the average session volume of 402,811 shares. The stock had previously closed at GBX 10.50.

Fusion Antibodies Price Performance

The company has a market cap of £13.40 million, a price-to-earnings ratio of -7.14 and a beta of 1.22. The company has a fifty day simple moving average of GBX 10.92 and a two-hundred day simple moving average of GBX 12.52. The company has a quick ratio of 2.36, a current ratio of 1.80 and a debt-to-equity ratio of 92.42.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.